Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12422648 | 0.94 | ALDH1A1 (0.48) | TSHRFAAHCASP2ALDH1A1LPAR1 | |
| SCHEMBL13339624 | 0.91 | TSHR (0.41) | TSHRFAAHCASP2ALDH1A1LPAR1 | |
| SCHEMBL10025175 | 0.86 | CASP2 (0.52) | FAAHCASP2ALDH1A1LPAR1NAAA | |
| SCHEMBL12417380 | 0.86 | LPAR1 (0.40) | FAAHALDH1A1LPAR1MAPTMEN1 | |
| SCHEMBL16015493 | 0.86 | SLC6A5 (0.50) | FAAHALDH1A1LPAR1DNM1MEN1 | |
| SCHEMBL18082922 | 0.85 | TSHR (0.37) | TSHRFAAHCASP2ALDH1A1LPAR1 | |
| SCHEMBL2607952 | 0.84 | TSHR (0.36) | TSHRFAAHALDH1A1LPAR1MEN1 | |
| SCHEMBL13225553 | 0.83 | ALDH1A1 (0.58) | TSHRFAAHCASP2ALDH1A1LPAR1 | |
| SCHEMBL20224856 | 0.81 | MEN1 (0.54) | TSHRALDH1A1MEN1KMT2ARECQL | |
| SCHEMBL17936383 | 0.79 | CASP2 (0.53) | FAAHCASP2ALDH1A1LPAR1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20140141483-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-05-22 | — | — | US | disclosed |
| US-8586711-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580919-B2 | Polymer conjugates of GLP-1 | NEKTAR THERAPEUTICS (US) | 2013-11-12 | — | — | US | disclosed |
| US-8420068-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2013-04-16 | — | — | US | disclosed |
| US-8273339-B2 | Polymer-based compositions and conjugates of antimicrobial agents | NEKTAR THERAPEUTICS (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110171160-A1 | POLYMER CONJUGATES OF KISS1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100160610-A1 | Conjugates of an EPO Moiety and a Polymer | NEKTAR THERAPEUTICS (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-7579444-B2 | Polymer-factor IX moiety conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | NEKTAR THERAPEUTICS | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171160-A1 | POLYMER CONJUGATES OF KISS1 PEPTIDES | KISS1R, PROKR1, NGLY1 | TSHR 3332/4885FAAH 3646/4885CASP2 4680/4885 |
| US-20110135623-A1 | Conjugates of a Cholinesterase Moiety and a Polymer | BCHE, ACHE, DNPEP | TSHR 2764/4885FAAH 513/4885CASP2 3897/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | TSHR 2396/4885FAAH 3471/4885CASP2 4219/4885 |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | TSHR 2749/4885FAAH 4134/4885CASP2 4103/4885 |
| US-20070092482-A1 | Conjugates of a G-CSF moiety and a polymer | CSF3R, GMFG, CSF1R | TSHR 2742/4885FAAH 3126/4885CASP2 4292/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | TSHR 1715/4885FAAH 4253/4885CASP2 2978/4885 |
| US-20100160610-A1 | Conjugates of an EPO Moiety and a Polymer | EPOR, EPRS1, NPPA | TSHR 1684/4885FAAH 3510/4885CASP2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.